The New Face Of Blockbuster Drugs
Blockbuster drugs are not going away but as science and market conditions continue to evolve and unmet needs shift to new territories, their profile is likely to change again. Companies can use strategies to offset the potential shortcomings of the new blockbuster model and improve their chances of becoming the successful players of tomorrow.
You may also be interested in...
FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.
Company scale is a negative predictor of value creation among biopharmaceutical companies, says a new analysis by L.E.K. Consulting, and industry’s largest companies have simply become too large to generate significant shareholder return going forward. How can the largest pharmaceutical companies adapt to an environment where they’ve become too big to succeed?
The success rates of late-stage molecules may prove to be higher than current analyst estimates; historical data suggests the biopharma industry has been fairly resilient in its ability to deliver its R&D pipeline while adapting to challenges.